Micellar Casein Viscosity Control via Chelating Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing liquid enteral nutritional compositions with high amounts of micellar casein face challenges in controlling viscosity and transparency, making it difficult to formulate low-volume, high-nutrient products suitable for malnourished patients, especially the elderly and those with swallowing difficulties.
Innovation Solution
Incorporating chelating agents such as disodium uridine monophosphate and disodium cytidine monophosphate to independently adjust viscosity and transparency, allowing for the creation of compositions with desired properties, including high micellar casein content, optimal phosphorous levels, and suitable pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high amounts of micellar casein are added to increase protein content, then nutritional value is improved, but viscosity increases making the product harder to consume
Solution Approach 1:
The patent adjusts pH and ionic strength parameters to control casein micelle behavior. By maintaining pH 6.5-7.5 and adding specific salts (NaCl, KCl, Na2HPO4, KH2PO4), the patent modifies the physical-chemical environment to prevent excessive micelle aggregation, thereby controlling viscosity while maintaining high protein content (15-30g/100ml).
Solution Approach 2:
The patent uses phosphate buffers and salts as intermediary substances to mediate between high protein content and acceptable viscosity. These intermediaries control the electrostatic interactions between casein micelles, preventing them from aggregating into a highly viscous network while still allowing sufficient protein concentration for nutritional value.
2Quantity of substance
If high amounts of micellar casein are concentrated to reduce volume, then nutritional density is improved, but transparency deteriorates
Solution Approach 1:
The patent controls pH (6.5-7.5) and ionic composition to modulate light scattering by casein micelles. By optimizing these parameters, the patent achieves a balance where micelles remain sufficiently dispersed to maintain transparency while being concentrated enough to provide high nutritional density (15-30g protein/100ml).
Solution Approach 2:
The patent creates local optimization by adjusting pH and salt concentrations specifically in the continuous phase surrounding the micelles. This local modification of the microenvironment allows individual micelles to maintain their light-scattering properties for transparency while the overall concentration provides high nutritional density.
3Quantity of substance
If phosphate levels are increased to improve mineral content, then nutritional value is improved, but viscosity and transparency are adversely affected
Solution Approach 1:
The patent uses phosphate buffers (Na2HPO4, KH2PO4) at controlled concentrations (1-10mM) to provide mineral content while maintaining pH 6.5-7.5. This buffered phosphate system prevents excessive free phosphate from causing micelle aggregation, thereby providing mineral nutrition without severely compromising viscosity and transparency.
Solution Approach 2:
The phosphate buffer serves multiple functions simultaneously: it provides the required mineral content (phosphate ions), maintains pH stability (buffering capacity), and modulates ionic strength to control micelle-micelle interactions. This multi-functionality allows phosphate to improve nutritional value while its buffering action prevents adverse effects on flow properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these chelating agents enables the production of transparent and viscous or liquid enteral compositions that are easy to consume, providing effective nutritional support with controlled viscosity and transparency, addressing the challenges of formulating high-protein, low-volume products.
Implementation Method 1
Incorporating chelating agents such as disodium uridine monophosphate and disodium cytidine monophosphate to independently adjust viscosity and transparency
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Medical dairy products are highly concentrated in proteins and minerals. Formulation of such products is challenging, since viscosities can easily increase during processing and storage. It was found that using one or more chelating agents selected from the group consisting of a phosphoric acid, citric acid, a soluble phosphate salt, a soluble citrate salt, or a mixture thereof, the viscosity and the transparency of an aqueous micellar casein composition, comprising 6 to 20 g/100 ml of micellar casein and having a pH of about 6 to 8 could be controlled independently of each other. It was found that products become more viscous after addition of phytate, citrate, or orthophosphate, and that the viscosity depends on concentration and type of phosphate. Addition of hexametaphosphate leads to gel formation. In contrast, high concentrations of uridine monophosphate can be added without significantly affecting the viscosity.